Pomalyst and Imbruvica drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pomalyst (pomalidomide) and Imbruvica (ibrutinib). Common drug interactions include cough among females and atrial fibrillation among males.

The phase IV clinical study analyzes what interactions people have when they take Pomalyst and Imbruvica. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. eHealthMe is studying from 80,400 Pomalyst users. Check the latest studies of Pomalyst.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

On Jul, 27, 2026

16 people who take Pomalyst and Imbruvica together, and have interactions are studied.

Pomalyst and Imbruvica drug interactions.

What are the common drug interactions of Pomalyst and Imbruvica, by gender? *:

female:

Cough
Hypoaesthesia (reduced sense of touch or sensation)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Anaemia (lack of blood)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Decreased appetite
Diarrhoea
Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Somnolence (a state of near-sleep, a strong desire for sleep)

male:

Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Peripheral swelling
Malaise (a feeling of general discomfort or uneasiness)
Pleural effusion (water on the lungs)
Weight decreased
Dehydration (dryness resulting from the removal of water)
Fatigue (feeling of tiredness)
General physical health deterioration (weak health status)
Influenza
Nausea (feeling of having an urge to vomit)

What are the common drug interactions of Pomalyst and Imbruvica, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Overweight

60+:

Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Cough
Syncope (loss of consciousness with an inability to maintain postural tone)
Vomiting
Renal impairment (severely reduced kidney function)
Diastolic dysfunction
Septic shock (shock due to blood infection)
Oedema peripheral (superficial swelling)
Peripheral swelling
Aphthous ulcer (mouth ulcer)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 12 people, 75.00%
Peripheral Sensory Neuropathy (damage to one or more of your peripheral nerves): 7 people, 43.75%
High Blood Pressure: 7 people, 43.75%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 7 people, 43.75%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 18.75%
Embolism Venous (embolus may pass into the arterial system): 3 people, 18.75%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Pomalyst and Imbruvica?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously